Latest Ratios: P/E Ratio 0.5x · EV/EBITDA N/A · ROE 7.8%. (2024–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Market Cap | $4M | $6M | $3M |
| Enterprise Value | $4M | $6M | $2M |
| P/E Ratio → | 0.52 | 0.86 | 0.52 |
| P/S Ratio | — | — | — |
| P/B Ratio | — | — | 0.01 |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Gross Margin | — | — | — |
| Operating Margin | — | — | — |
| Net Profit Margin | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| ROE | 7.8% | 7.8% | 2.3% |
| ROA | 3.4% | 3.4% | 2.2% |
| ROIC | -1.1% | -1.1% | — |
| ROCE | -0.7% | -0.7% | -0.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Debt / Equity | — | — | — |
| Debt / EBITDA | — | — | — |
| Net Debt / Equity | — | — | -0.00 |
| Net Debt / EBITDA | — | — | — |
| Debt / FCF | — | — | — |
| Interest Coverage | — | — | — |
Net cash position: cash ($30146) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Current Ratio | 0.23 | 0.23 | 9.67 |
| Quick Ratio | 0.23 | 0.23 | 9.67 |
| Cash Ratio | 0.04 | 0.04 | 7.79 |
| Asset Turnover | — | — | — |
| Inventory Turnover | — | — | — |
| Days Sales Outstanding | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Earnings Yield | 100.0% | 116.0% | 192.6% |
| FCF Yield | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $23M | $19M |
Sponsor dependency and liquidation
According to recent financial data, the company's P/E ratio of 0.52 is fundamentally misleading, as it reflects non-cash warrant fair value adjustments rather than operational earnings, suggesting that market participants are pricing the equity based on the probability of a successful merger rather than any underlying business performance.
The current valuation multiple is essentially a proxy for the perceived likelihood of a high-upside life sciences acquisition. Investors should monitor that this metric lacks predictive power for future cash flows, as the company remains a pre-revenue shell entity.
Based on reported figures, the current ratio has deteriorated from 7.05 in 2025Q1 to 0.30 in 2026Q1, indicating that the firm's liquidity position is increasingly strained as the available cash outside of the restricted trust account is depleted by ongoing administrative and due diligence expenses.
The sharp decline in the current ratio suggests that the company is approaching a critical juncture where sponsor support may be required to maintain operations. This trend warrants further investigation into the sponsor's willingness to provide additional working capital loans to avoid a premature liquidation.
As reported in financial statements, the company's ROIC has trended into negative territory, reaching -0.4% in 2025Q3, which highlights the inherent inefficiency of holding capital in a shell structure while incurring fixed costs without any offsetting revenue generation from a target business combination.
The negative return on capital is a structural reality of the SPAC lifecycle rather than a failure of management strategy. However, the persistent decay suggests that the longer the search for a target continues, the more the intrinsic value of the initial capital is eroded by administrative burn.
Investors frequently misapply P/E ratios to this business model, as reported in financial filings, which obscures the fact that net income is driven by non-operating warrant revaluations rather than core business activity, rendering traditional valuation multiples largely irrelevant for assessing the firm's true economic health.
Analysts should instead focus on the trust account balance and the remaining time in the merger window to gauge the firm's potential. Relying on earnings-based metrics for a pre-combination shell company may lead to a fundamental misunderstanding of the risk-reward profile inherent in the sponsor's mandate.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LPAAW stock.
Launch One Acquisition Corp.'s current P/E ratio is 0.5x. The historical average is 0.7x. This places it at the 50th percentile of its historical range.
Launch One Acquisition Corp.'s return on equity (ROE) is 7.8%. The historical average is 5.0%.
Based on historical data, Launch One Acquisition Corp. is trading at a P/E of 0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.